Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synapse 3D and ICG for Targeted Pulmonary Segmental Resection in NSCLC
NCT03953144Phase 2Recruiting
- Sponsor
- St. Joseph's Healthcare Hamilton
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in non-small cell lung cancer (NSCLC), sponsored by St. Joseph's Healthcare Hamilton. Primary endpoints: Segmental Resection Conversion Rate at 1 year and Number of Participants with Post Operative Complications at 1 year. Started Dec 2022; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03953144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953144.